-
Areas
Technologies
Themes / Divisions

About

Dr Doerflinger completed a Master of Science Degree with focus on Biochemistry and Immunology at the University of Stuttgart, Germany. Dr Doerflinger then moved to Australia in February 2012 to undertake PhD studies under the supervision of Associate Professor Hamsa Puthalakath at La Trobe University, and their work on cell death regulation resulted in several first author publications.

In 2016, they took up a position as Postdoctoral Fellow in the Pellegrini laboratory at WEHI, where they expanded their skillset and career focus towards translational outcomes and have built productive collaborative networks nationally (such as The Peter Doherty Institute, Hudson Institute, La Trobe University, Peter MacCallum Cancer Centre, MCRI and The Florey) and internationally (Austria, Germany, Japan, US).

Dr Doerflinger has recently been appointed Laboratory Head at WEHI and in this role oversees the PC3 facility within the Infectious Diseases and Immune Defense division. This is the basis to lead a comprehensive research program in which Dr Doerflinger continues to uncover the regulatory processes of programmed cell death processes and their contribution to shaping immune responses to infection.

Publications

Selected publications from Dr Marcel Doerflinger

Muhi S, Marshall JL, O’Brien DP, Johnson PDR, Ross G, Ramakrishnan A, Mackay LK, Doerflinger M, McCarthy JS, Jamrozik E, Osowicki J, Stinear TP. A human model of Buruli ulcer: Provisional protocol for a Mycobacterium ulcerans controlled human infection study.Wellcome Open Research. 2024;9:10.12688/wellcomeopenres.22719.1

Muhi S, Buultjens AH, Porter JL, Marshall JL, Doerflinger M, Pidot SJ, O’Brien DP, Johnson PDR, Lavender CJ, Globan M, McCarthy J, Osowicki J, Stinear TP. Mycobacterium ulcerans challenge strain selection for a Buruli ulcer controlled human infection model. PLOS Neglected Tropical Diseases. 2024;18(5):10.1371/journal.pntd.0011979

M. Bader S, Cooney JP, Bhandari R, Mackiewicz L, Dayton M, Sheerin D, Georgy SR, Murphy JM, Davidson KC, Allison CC, Pellegrini M, Doerflinger M. Necroptosis does not drive disease pathogenesis in a mouse infective model of SARS-CoV-2 in vivo. Cell Death & Disease. 2024;15(1):10.1038/s41419-024-06471-6

Garnish SE, Martin KR, Kauppi M, Jackson VE, Ambrose R, Eng VV, Chiou S, Meng Y, Frank D, Tovey Crutchfield EC, Patel KM, Jacobsen AV, Atkin-Smith GK, Di Rago L, Doerflinger M, Horne CR, Hall C, Young SN, Cook M, Athanasopoulos V, Vinuesa CG, Lawlor KE, Wicks IP, Ebert G, Ng AP, Slade CA, Pearson JS, Samson AL, Silke J, Murphy JM, Hildebrand JM. A common human MLKL polymorphism confers resistance to negative regulation by phosphorylation. Nature Communications. 2023;14(1):10.1038/s41467-023-41724-6

Arandjelovic P, Kim Y, Cooney JP, Preston SP, Doerflinger M, McMahon JH, Garner SE, Zerbato JM, Roche M, Tumpach C, Ong J, Sheerin D, Smyth GK, Anderson JL, Allison CC, Lewin SR, Pellegrini M. Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice. Cell Reports Medicine. 2023;4(9):10.1016/j.xcrm.2023.101178

Bader SM, Cooney JP, Sheerin D, Taiaroa G, Harty L, Davidson KC, Mackiewicz L, Dayton M, Wilcox S, Whitehead L, Rogers KL, Georgy SR, Coussens AK, Grimley SL, Corbin V, Pitt M, Coin L, Pickering R, Thomas M, Allison CC, McAuley J, Purcell DFJ, Doerflinger M, Pellegrini M. SARS-CoV-2 mouse adaptation selects virulence mutations that cause TNF-driven age-dependent severe disease with human correlates. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(32):10.1073/pnas.2301689120

Muhi S, Osowicki J, O’Brien D, Johnson PDR, Pidot S, Doerflinger M, Marshall JL, Pellegrini M, McCarthy J, Stinear TP. A human model of Buruli ulcer: The case for controlled human infection and considerations for selecting a Mycobacterium ulcerans challenge strain. PLOS Neglected Tropical Diseases. 2023;17(6):10.1371/journal.pntd.0011394

Hughes SA, Lin M, Weir A, Huang B, Xiong L, Chua NK, Pang J, Santavanond JP, Tixeira R, Doerflinger M, Deng Y, Yu C, Silke N, Conos SA, Frank D, Simpson DS, Murphy JM, Lawlor KE, Pearson JS, Silke J, Pellegrini M, Herold MJ, Poon IKH, Masters SL, Li M, Tang Q, Zhang Y, Rashidi M, Geng L, Vince JE. Caspase‐8‐driven apoptotic and pyroptotic crosstalk causes cell death and IL‐1β release in X‐linked inhibitor of apoptosis (XIAP) deficiency. The EMBO Journal. 2023;42(5):10.15252/embj.2021110468

Preston SP, Allison CC, Schaefer J, Clow W, Bader SM, Collard S, Forsyth WO, Clark MP, Garnham AL, Li-Wai-Suen CSN, Peiris T, Teale J, Mackiewicz L, Davidson S, Doerflinger M, Pellegrini M. A necroptosis-independent function of RIPK3 promotes immune dysfunction and prevents control of chronic LCMV infection. Cell Death & Disease. 2023;14(2):10.1038/s41419-023-05635-0

Preston SP, Stutz MD, Allison CC, Nachbur U, Gouil Q, Tran BM, Duvivier V, Arandjelovic P, Cooney JP, Mackiewicz L, Meng Y, Schaefer J, Bader SM, Peng H, Valaydon Z, Rajasekaran P, Jennison C, Lopaticki S, Farrell A, Ryan M, Howell J, Croagh C, Karunakaran D, Schuster-Klein C, Murphy JM, Fifis T, Christophi C, Vincan E, Blewitt ME, Thompson A, Boddey JA, Doerflinger M, Pellegrini M. Epigenetic Silencing of RIPK3 in Hepatocytes Prevents MLKL-mediated Necroptosis From Contributing to Liver Pathologies. Gastroenterology. 2022;163(6):10.1053/j.gastro.2022.08.040

Lab research projects

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.